Participants will match targeted therapies to specific genetic mutations. Key Features: ● Case studies: Real-world scenarios requiring selection of appropriate targeted therapies. ● Drag-and-drop interface: For selecting and applying treatments. ● Explanatory feedback: Detailed explanations for each treatment choice.

Course Accreditations

This activity is supported with Independent Medical Education Grants from: Exact Sciences Pfizer Puma Biotechnology Novartis 0.75 AMA PRA Category 1 Credit™ The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission. 0.75 Nursing Contact Hours Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours. 0.75 ABIM MOC II Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Course Summary

Target Audience

Hematologists/Oncologists
Oncology Nurse Practitioners
Oncology Pharmacists
Oncology Physician Assistants
Oncology Fellows/Residents
Oncology Nurses
Researchers and others involved in the care of cancer patients

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
Explain the role, including advantages and disadvantages, of different testing methodologies available for a selection of targeted therapies.
Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in a clinical investigation for cancer patients.